PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma

Multiple Myeloma Clinical Trial

— iPREFER  

Official title:

PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06322927
• Other study ID #: CFTsp231
• Secondary ID: 24_CPCR_38
• Status: Not yet recruiting
• Start date: March 31, 2024
• Est. completion date: September 30, 2024

Study information

• Verified date: March 2024
• Source: The Christie NHS Foundation Trust
• Contact: Sally Taylor, PhD
• Phone: 0161 446 3597
• Email: sally.taylor38[@]nhs.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to them when making treatment decisions.

Description:

People can receive many lines of treatment for multiple myeloma. We would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to them when considering treatment options, how their experiences have differed with different treatments and if they have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. They will be asked to participate in an interview which should take approximately 30 minutes to an hour. During the interview they will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: September 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants with confirmed MM (per standard disease specific diagnostic criteria)

2. Participants must have received = 5 lines of treatment for MM and fit into one of the below treatment categories:

1. Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment.

2. Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy.

3. Aged 18 years of age or over

4. Able to provide informed consent

5. Able to communicate in English

Exclusion Criteria:

1. Aged under 18

2. Unable to understand and communicate in the English language

3. Unable to provide written informed consent

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Other:
• Patient Interview
Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.

Locations

Country	Name	City	State
United Kingdom	The Christie NHS Foundation Trust	Manchester	Greater Manchester

Sponsors (2)

Lead Sponsor	Collaborator
The Christie NHS Foundation Trust	CellCentric Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient Experience and Preference	The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.	30-60 minutes
Secondary	Treatment and Preference Differences	The interview will explore how experiences have differed across different lines of treatment and determine if people with multiple myeloma have any preferences for particular treatments.	30-60 minutes